National Institute on Drug Abuse; Notice of Closed Meeting, 74739-74740 [2020-25800]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 226 / Monday, November 23, 2020 / Notices
Despite the widespread availability of
effective vaccines, vaccine-preventable
diseases (VPDs) remain a significant
public health challenge. In particular,
rates of non-medical exemptions for
childhood vaccines are increasing,4 and
there have been recent measles
outbreaks in the U.S.5 and globally, due
to growing vaccine hesitancy and
coverage levels below the threshold
needed for herd immunity. With an
estimated cost of $20,000 per case of
measles to the public sector in 2016,6
the economic consequences of this and
other VPDs, as well as the health
consequences, are significant.
Furthermore, few adults in any age
group are fully vaccinated as
recommended by the Advisory
Committee on Immunization Practices.2
Large disparities in vaccine coverage by
race/ethnicity persist, with African
Americans, Hispanics, and Asian
Americans lagging behind whites in
nearly all vaccination coverage rates.7
VPDs such as pertussis and hepatitis B
continue to take a heavy toll on public
health,8 with 18,975 cases of pertussis
and 3,409 (22,000 estimated) cases of
hepatitis B infections reported in the
United States in 2017.9 10 In light of
these challenges, strengthening the
vaccine and immunization enterprise is
a priority for HHS.
To respond to the public health
challenges of VPDs, OIDP in
collaboration with other federal partners
is leading the development of the
Vaccines National Strategic Plan
(Vaccine Plan). This updated plan will
recommend vaccine strategies across the
lifespan and guide priority actions for
the period 2021–2025. While COVID–19
and coronavirus vaccine development
are currently changing the landscape of
the vaccine enterprise, the Vaccine Plan
Advisory Committee: Standards for adult
immunization practice. Public Health Rep.
2014;129:115–23.
4 Omer, S. et al. Nonmedical exemptions to
school immunization requirements: Secular trends
and association of state policies with pertussis
incidence. JAMA. 2006;296(14):1757–1763.
5 https://www.cdc.gov/measles/casesoutbreaks.html.
6 Lo NC, Hotez P.J. Public Health and Economic
Consequences of Vaccine Hesitancy for Measles in
the United States. JAMA Pediatr. 2017;171(9):887–
892. doi:10.1001/jamapediatrics.2017.1695.
7 Lu P.J. et al. Racial and Ethnic Disparities in
Vaccination Coverage Among Adult Populations in
the U.S. Am J. Prev Med. 2015;49(6 Suppl 4):S412–
S425. doi:10.1016/j.amepre.2015.03.005.
8 https://www.cdc.gov/vaccines/pubs/pinkbook/
downloads/appendices/e/reported-cases.pdf.
9 https://www.chop.edu/centers-programs/
vaccine-education-center/global-immunization/
diseases-and-vaccines-world-view.
10 Schillie et al. Prevention of Hepatitis B Virus
Infection in the United States: Recommendations of
the Advisory Committee on Immunization
Practices. MMWR. 2018;67(1):1–31.
VerDate Sep<11>2014
17:07 Nov 20, 2020
Jkt 253001
has a broad focus on the entire vaccine
enterprise and is not focused
specifically on any one vaccine or the
pandemic response. HHS, through
OIDP, seeks input regarding the draft of
the Vaccine Plan from subject matter
experts and nonfederal partners and
stakeholders such as health care
providers, national professional
organizations, health departments,
school administrators, communitybased and faith-based organizations,
manufacturers, researchers, advocates,
and persons affected by VPDs.
The following are the Vaccine Plan’s
vision and goals. Vision: United States
will be a place where vaccinepreventable diseases are eliminated
through safe and effective vaccination
over the lifespan. Goals:
1. Foster innovation in vaccine
development and related technologies.
2. Maintain the highest possible levels
of vaccine safety.
3. Increase knowledge of and
confidence in routinely recommended.
4. Increase access to and use of all
routinely recommended vaccines.
5. Protect the health of the American
public by supporting global
immunization efforts.
Information Needs
The draft Vaccine Plan may be
reviewed at www.hhs.gov/oidp.
OIDP seeks to obtain feedback from
external stakeholders on the following:
1. Do the draft Vaccine Plan’s goals,
objectives, and strategies appropriately
address the vaccine landscape?
2. Are there any critical gaps in the
Vaccine Plan’s goals, objectives, and
strategies? If so, please specify the gaps.
3. Do any of the Vaccine Plan’s goals,
objectives and strategies cause concern?
If so, please specify the goal, objective
or strategy, and describe the concern
regarding it.
Please be succinct and limit your
comments to a maximum of seven
pages.
Authority: 42 U.S.C. Section 300aa–3.
Dated: November 17, 2020.
B. Kaye Hayes,
Acting Director, Office of Infectious Disease
and HIV/AIDS Policy.
[FR Doc. 2020–25842 Filed 11–20–20; 8:45 am]
BILLING CODE 4150–43–P
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
74739
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
Mental Health Services Research Special
Emphasis Panel.
Date: December 17, 2020.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Nicholas Gaiano, Ph.D.,
Review Branch Chief, Division of Extramural
Activities, National Institute of Mental
Health, NIH, Neuroscience Center/Room
6150/MSC 9606, 6001 Executive Boulevard,
Bethesda, MD 20892–9606, 301–443–2742,
nick.gaiano@nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
Dated: November 17, 2020.
Patricia B. Hansberger,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2020–25749 Filed 11–20–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
E:\FR\FM\23NON1.SGM
23NON1
74740
Federal Register / Vol. 85, No. 226 / Monday, November 23, 2020 / Notices
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; DEACompliant Drug Detection and Deactivation
Technology to Deter Opioid Theft in
Hospitals for Next Generation Controlled
Substance Diversion Prevention Program
(CSDPP)
Date: December 15, 2020.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Soyoun Cho, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 594–9460,
Soyoun.cho@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: November 17, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–25800 Filed 11–20–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
VerDate Sep<11>2014
17:07 Nov 20, 2020
Jkt 253001
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Preclinical and
Translational Vaccine Development Support
for HIV and Other Candidate Agents (PTVDS)
(N01), Task Areas C and D.
Date: December 17, 2020.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G31,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Cynthia L. De La Fuente,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G31,
Rockville, MD 20852, 240–669–2740,
delafuentecl@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 17, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–25798 Filed 11–20–20; 8:45 am]
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G31,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Cynthia L. De La Fuente,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G31,
Rockville, MD 20852, 240–669–2740,
delafuentecl@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 17, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–25799 Filed 11–20–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Preclinical and
Translational Vaccine Development Support
for HIV and Other Candidate Agents
(PTVDS), Task Areas A and B.
Date: December 14, 2020.
Time: 10:00 a.m. to 6:00 p.m.
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel NIAID Investigator Initiated
Program Project Applications (P01 Clinical
Trial Not Allowed).
Date: December 16, 2020.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G60,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Gregory P. Jarosik, Ph.D.
Scientific Review Program, Division of
Extramural Activities, National Institute of
Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room
3G60, Rockville, MD 20852, (240) 669–5080,
gjarosik@niaid.nih.gov.
E:\FR\FM\23NON1.SGM
23NON1
]]>Agencies
[Federal Register Volume 85, Number 226 (Monday, November 23, 2020)]
[Notices]
[Pages 74739-74740]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-25800]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C.,
[[Page 74740]]
as amended. The contract proposals and the discussions could disclose
confidential trade secrets or commercial property such as patentable
material, and personal information concerning individuals associated
with the contract proposals, the disclosure of which would constitute a
clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; DEA-Compliant Drug Detection and Deactivation
Technology to Deter Opioid Theft in Hospitals for Next Generation
Controlled Substance Diversion Prevention Program (CSDPP)
Date: December 15, 2020.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Soyoun Cho, Ph.D., Scientific Review Officer,
Scientific Review Branch, Division of Extramural Research, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 594-9460, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: November 17, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-25800 Filed 11-20-20; 8:45 am]
BILLING CODE 4140-01-P
